0001209191-21-053350.txt : 20210825 0001209191-21-053350.hdr.sgml : 20210825 20210825174536 ACCESSION NUMBER: 0001209191-21-053350 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210823 FILED AS OF DATE: 20210825 DATE AS OF CHANGE: 20210825 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kalowski Lee CENTRAL INDEX KEY: 0001618273 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38916 FILM NUMBER: 211208033 MAIL ADDRESS: STREET 1: C/O TOKAI PHARMACEUTICALS, INC. STREET 2: ONE BROADWAY, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc CENTRAL INDEX KEY: 0001761612 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT BUSINESS PHONE: 011441223261503 MAIL ADDRESS: STREET 1: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT FORMER COMPANY: FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd DATE OF NAME CHANGE: 20181212 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-08-23 0 0001761612 BICYCLE THERAPEUTICS plc BCYC 0001618273 Kalowski Lee C/O BICYCLE THERAPEUTICS PLC B900, BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT UNITED KINGDOM 0 1 0 0 President and CFO Ordinary Shares 2021-08-23 4 M 0 7500 1.60 A 7500 D Ordinary Shares 2021-08-23 4 S 0 7500 33.02 D 0 D Stock Option (Right to Buy) 1.60 2021-08-23 4 M 0 7500 0.00 D 2027-07-23 Ordinary Shares 7500 59774 D Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.366815 to GBP 1.00 as of August 23, 2021. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.056 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 20% of the shares subject to the option vested on July 24, 2018, 60% of the shares subject to the option will vest each month thereafter in 36 equal monthly installments, and the remaining 20% of the shares subject to the option will vest on the earlier of (i) the fourth anniversary of the grant date and (ii) the date on which the Issuer's board of directors determines that the Issuer has satisfied certain performance vesting milestones, in all cases provided that the Reporting Person remains continuously employed with us through each applicable vesting date. /s/ Lee Kalowski 2021-08-25